arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Co-Diagnostics, Inc.

CODX
$1.50 ▲ +0.08 (+5.63%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
41 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Co-Diagnostics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.4M
Dividend Yield
Revenue Growth 190.3%
Op. Margin None
ROIC -57.4%
FCF / Share $-3.54
Trailing P/E
Price / Book 0.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$145.95K
↑ +190.3%
Net Income Profit after all expenses
$-9.14M
↓ -21.3%
Operating Margin Operating profit as % of sales
-289.1%
↑ +13.1%
FCF / Share Free cash flow per share
$-3.54
↓ -1185.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 41 quarters